Kura Oncology, Inc.·4

Jun 4, 6:30 PM ET

Parks Diane L. 4

4 · Kura Oncology, Inc. · Filed Jun 4, 2026

Research Summary

AI-generated summary of this filing

Updated

Kura Oncology (KURA) Director Diane L. Parks Receives 35,000-Share Option Award

What Happened

  • Diane L. Parks, a director of Kura Oncology (KURA), was granted a derivative award on 2026-06-04 representing the right to acquire 35,000 shares. The filing reports an acquisition at $0.00 (no cash exchanged at grant). Footnote states the option vests in full on the one-year anniversary of the grant.

Key Details

  • Transaction date: 2026-06-04; Transaction code: A (award/grant)
  • Quantity: 35,000 shares; Reported price: $0.00 (derivative/option grant)
  • Shares owned after transaction: Not specified in the filing
  • Footnote: Option vests in full on the one-year anniversary of the grant (F1)
  • Filing timeliness: Reported on 2026-06-04 for the same date — appears timely

Context

  • This is a grant of an option-style award (a compensatory derivative), not a cash purchase or sale. Grants to directors are common as compensation and typically vest over time; they do not by themselves indicate buying or selling interest in the open market. The filing does not show an exercise price or immediate sale of shares — those details, if any, would appear in future filings.

Insider Transaction Report

Form 4
Period: 2026-06-04
Transactions
  • Award

    Option to purchase common stock

    [F1]
    2026-06-04+35,00035,000 total
    Exercise: $8.77Exp: 2036-06-03Common Stock (35,000 underlying)
Footnotes (1)
  • [F1]This option vests in full on the one year anniversary of the date of grant.
Signature
/s/ Teresa Bair, Attorney-in-fact for Diane Parks|2026-06-04

Documents

1 file
  • 4
    ownership.xmlPrimary

    4